Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study

Sabrina Chiloiro, Antonio Bianchi, Laura De Marinis Grasso, Antonella Giampietro, Gherardo Mazziotti, Claudia Battista, Filippo Maffezzoni, Emanuele Ferrante, Nunzia Prencipe, Ludovica Grasso, Federico Gatto, Roberto Olivetti, Maura Arosio, Marco Barale, Miriam Cellini, Iacopo Chiodini, Giulia Del Sindaco, Carolina Di Somma, Alberto Ferlin, Ezio GhigoSilvia Grottoli, Elisabetta Lavezzi, Giovanna Mantovani, Emanuela Morenghi, Rosario Pivonello, Teresa Porcelli, Massimo Procopio, Flavia Pugliese, Alfredo Scillitani, Andrea Gerardo Lania

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Background: Vertebral fractures (VFs) are a frequent complication of acromegaly, but no studies have been so far published on effectiveness of antiosteoporotic drugs in this clinical setting. Objective: To evaluate whether in real-life clinical practice bone active drugs may reduce the risk of VFs in patients with active or controlled acromegaly. Study design: Retrospective, longitudinal study including 9 tertiary care endocrine units. Patients and methods: Two hundred and forty-eight patients with acromegaly (104 males; mean age 56.00 ± 13.60 years) were evaluated for prevalent and incident VFs by quantitative morphometric approach. Bone active agents were used in 52 patients (20.97%) and the median period of follow-up was 48 months (range 12-132). Results: During the follow-up, 65 patients (26.21%) developed incident VFs in relationship with pre-existing VFs (odds ratio [OR] 3.75; P < .001), duration of active acromegaly (OR 1.01; P = .04), active acromegaly at the study entry (OR 2.48; P = .007), and treated hypoadrenalism (OR 2.50; P = .005). In the entire population, treatment with bone active drugs did not have a significant effect on incident VFs (P = .82). However, in a sensitive analysis restricted to patients with active acromegaly at study entry (111 cases), treatment with bone active drugs was associated with a lower risk of incident VFs (OR 0.11; P = .004), independently of prevalent VFs (OR 7.65; P < .001) and treated hypoadrenalism (OR 3.86; P = .007). Conclusions: Bone active drugs may prevent VFs in patients with active acromegaly.
Lingua originaleEnglish
pagine (da-a)3285-3292
Numero di pagine8
RivistaTHE JOURNAL OF CLINICAL ENDOCRINOLOGY &amp; METABOLISM
Stato di pubblicazionePubblicato - 2020

Keywords

  • acromegaly

Fingerprint

Entra nei temi di ricerca di 'Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study'. Insieme formano una fingerprint unica.

Cita questo